Vibliome logo Vibliome logo

Vibliome Therapeutics, LLC, has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique profiles and a very high degree of selectivity.

Learn More

down arrow

About Vibliome

There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.

In contrast to target-driven high throughput screening, Vibliome’s inverted discovery paradigm utilizes early profiling of its novel inhibitor library against a broad kinase panel as its foundation.

This screening strategy coupled with our unique chemical architecture generates a powerful platform for mining the kinase inhibitor space. In conjunction with structure-guided design efforts, our approach has produced unique high-quality targeted therapy leads that are poised for optimization and advancement to provide new therapeutic options, particularly in oncology.

Our mission to develop new therapeutic options for patients is backed by Deerfield Management in New York, a private equity firm committed to improving healthcare through investment, information and philanthropy.

Vibliome Careers

Vibliome’s research operations are located in Bozeman, Montana on the edge of Yellowstone National Park and in the midst of world class skiing, fly fishing, unsurpassed access to nature and Montana’s largest research university.

View Open Positions

Vibliome News

Vibliome Therapeutics Expands Its Kinase Inhibitor Discovery Library

January 11, 2021

Vibliome Therapeutics, LLC, announced today that it has expanded its highly curated proprietary kinase inhibitor discovery library to more than 500 unique compounds. This library is built on a common chemotype the company is leveraging for the development of novel therapeutics targeting clinically relevant cell signaling pathways.

Read More


Vibliome Therapeutics Closes First Tranche of Its $16 million Series A Financing Round to Advance Selective Kinase Inhibitor Technology for Oncology and Other Disease Applications

April 29, 2019

Vibliome Therapeutics, LLC, announced that it closed a $16mm Series A round of financing to advance its proprietary technology supporting the development of small molecule therapeutics targeting clinically-relevant signaling pathways. Deerfield Management was the sole investor in the Series A financing round and will be providing operational support.

Read More

Vibliome Team


Robert Goodwin, PhD

Chief Executive Officer

LinkedIn logo

James Grenzebach

VP Operations

LinkedIn logo

Frank Hollinger, PhD

VP Chemoinformatics

LinkedIn logo

Paul Galatsis, PhD

VP Chemistry

LinkedIn logo

Board of Directors

Robert Goodwin, PhD

Chief Executive Officer

Jason Fuller, PhD

Deerfield Management

Cameron Wheeler, PhD

Deerfield Management

Scientific Advisory Board

Keith Flaherty, MD

Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Massachusetts General Hospital Cancer Center, Boston, MA

Dejan Juric, MD

Director, Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program, and Program Director, Investigational Cancer Therapeutics Program, Massachusetts General Hospital Cancer Center, Boston MA

Eric Springman, PhD

Chief Scientific Officer, Celtaxsys, Inc.

Ken Westover, MD PhD

Associate Professor of Radiation Oncology and Biochemistry, Director of Clinical Innovation and Information Technology, Department of Radiation Oncology, University of Texas Southwestern, Dallas TX

Kwok-Kin Wong, MD, PhD

Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine; Director, Division of Hematology and Medical Oncology, New York University Langone Health

533 East Mendenhall St, Bozeman, MT 59715 USA

345 Park Avenue South, New York, NY 10010

+1 (406) 595-3483